Advancing Neuroprotective-Based Treatments for Schizophrenia

Ritsner, Michael S.; Lerner, Vladimir

doi:10.1007/978-94-007-0834-1_3

Cited by 7 publications

(6 citation statements)

References 154 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Schizophrenia is a profoundly debilitating illness currently ranking among the top 10 causes of long-term disability worldwide [ 2 ], which imposes a significant financial burden on public health services as it is one of the most financially costly psychiatric disorders to manage [ 3 ]. The profound impact of the disorder is reflected in the fact that approximately 70–92% of patients with schizophrenia are unemployed [ 4 ]. Additionally, people with schizophrenia are 13-fold more likely to die by suicide than are members of the general population [ 5 ], and also have a life expectancy 10–25 years less, even after accounting for suicide [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings

Gogos

Sbisa

Sun

et al. 2015

International Journal of Endocrinology

182

119

View full text Add to dashboard Cite

Gender differences in schizophrenia have been extensively researched and it is being increasingly accepted that gonadal steroids are strongly attributed to this phenomenon. Of the various hormones implicated, the estrogen hypothesis has been the most widely researched one and it postulates that estrogen exerts a protective effect by buffering females against the development and severity of the illness. In this review, we comprehensively analyse studies that have investigated the effects of estrogen, in particular 17β-estradiol, in clinical, animal, and molecular research with relevance to schizophrenia. Specifically, we discuss the current evidence on estrogen dysfunction in schizophrenia patients and review the clinical findings on the use of estradiol as an adjunctive treatment in schizophrenia patients. Preclinical research that has used animal models and molecular probes to investigate estradiol's underlying protective mechanisms is also substantially discussed, with particular focus on estradiol's impact on the major neurotransmitter systems implicated in schizophrenia, namely, the dopamine, serotonin, and glutamate systems.

show abstract

Section: Introductionmentioning

confidence: 99%

A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings

Gogos

Sbisa

Sun

et al. 2015

International Journal of Endocrinology

182

119

View full text Add to dashboard Cite

show abstract

“…1 It is one of the mental illnesses with the most impact on life and associated with poorest lifelong outcomes, and has the greatest variation in access to evidence-based informed care. 2 Up to two-thirds of the current psychiatric hospital population are experiencing psychosis internationally. 3 Compulsory admissions to a psychiatric hospital are high, with people experiencing psychosis being the most likely group to be forcibly detained.…”

mentioning

confidence: 99%

The therapeutic needs of psychiatric in-patients with psychosis: A qualitative exploration of patient and staff perspectives

2019

View full text Add to dashboard Cite

Background Concerns are recurrently expressed that the therapeutic content of in-patient care is limited and lacking clear guidance. The perspectives of patients and staff regarding therapeutic priorities for psychiatric in-patient care have been little explored and compared. Aims The aim of this study was to examine patient and staff perspectives on the care priorities of psychiatric in-patients with psychosis. Method We recruited 12 in-patients with psychosis and 12 multidisciplinary team staff. All participants undertook a semi-structured interview examining their perspectives on the therapeutic needs of people with psychosis during admission. Interviews were transcribed verbatim and thematic analysis conducted. Results Three superordinate themes arose from patient interviews: ‘the importance of considering social circumstances and trauma’, ‘managing the intra- and interpersonal impact of psychosis’ and ‘lack of control and collaboration in care’ and three from staff interviews: ‘multidisciplinary facilitators of care’, ‘treating complexity and incorporating social factors’ and ‘restrictive practices preventing quality care provision’. Comparison of patient and staff themes identified unmet needs in addressing social marginalisation, trauma and distress, and the importance of collaborative treatment process and inclusion of spirituality. Conclusions There are gaps between staff and patient perspectives on important priorities for in-patient care that may help explain persistent patient dissatisfaction with in-patient care. Findings suggest the need for coproduced work to develop and test interventions that address broader therapeutic priorities. Declaration of interest None.

show abstract

“…Hence these three genes are considered significant biomarkers of COVID-19. Higher levels of Malate Dehydrogenase 1 (MDH1) was associated with schizophrenia (Ritsner, 2011 ), prions disease (Zerr et al, 2019 ) and early onset of encephalopathy (Broeks et al, 2019 ). Elevation of SGCE Sarcoglycan-epsilon gene was attributed to muscular dystrophy (Emery, 2001 ).…”

Section: Discussionmentioning

confidence: 99%

Computational gene expression profiling in the exploration of biomarkers, non-coding functional RNAs and drug perturbagens for COVID-19

Aishwarya

Gunasekaran

Margret³

2020

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

The coronavirus disease, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a global health crisis that is being endured with an increased alarm of transmission each day. Though the pandemic has activated innumerable research attention to decipher an antidote, fundamental understanding of the molecular mechanisms is necessary to halt the disease progression. The study focused on comparison of the COVID-19 infected lung tissue gene expression datasets-GSE155241 and GSE150316 with the GEO2R-limma package. The significant up-and downregulated genes were annotated. Further evaluation of the enriched pathways, transcription factors, kinases, noncoding RNAs and drug perturbations revealed the significant molecular mechanisms of the host response. The results revealed a surge in mitochondrial respiration, cytokines, neurodegenerative mechanisms and deprived oxygen, iron, copper, and glucose transport. Hijack of ubiquitination by SARS-CoV-2, hox gene differentiation, histone modification, and miRNA biogenesis were the notable molecular mechanisms inferred. Long non-coding RNAs such as C058791.1, TTTY15 and TPTEP1 were predicted to be efficient in regulating the disease mechanisms. Drugs-F-1566-0341, Digoxin, Proscillaridin and Linifanib that reverse the gene expression signatures were predicted from drug perturbations analysis. The binding efficiency and interaction of proscillaridin and digoxin as obtained from the molecular docking studies confirmed their therapeutic potential. Two overlapping upregulated genes MDH1, SGCE and one downregulated gene PFKFB3 were appraised as potential biomarkers candidates. The upregulation of PGM5, ISLR and ANK2 as measured from their expressions in normal lungs affirmed their possible prognostic biomarker competence. The study explored significant insights for better diagnosis, and therapeutic options for COVID-19.

show abstract

Advancing Neuroprotective-Based Treatments for Schizophrenia

Cited by 7 publications

References 154 publications

A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings

A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings

The therapeutic needs of psychiatric in-patients with psychosis: A qualitative exploration of patient and staff perspectives

Computational gene expression profiling in the exploration of biomarkers, non-coding functional RNAs and drug perturbagens for COVID-19

Contact Info

Product

Resources

About